Angle is moving ahead with plans to take its Parsortix circulating tumor cell capture technology into the prostate and breast cancer diagnostic markets after securing £10.2m ($15m) in new capital through a share placement.
The system is designed to harvest circulating tumor cells (CTCs) from a patient’s blood sample with a label-free approach that relies on the tumor cells’ physical characteristics to separate them...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?